Wave data underwhelms, and its stock tanks

Share of Wave Life Sciences were decimated yesterday, down 50%. The cause: Data from an early stage Huntington’s disease trial for its experimental antisense drug paled in comparison to the efficacy of a similar antisense drug from Roche and Ionis, as FierceBiotech points out.

Indeed, Jefferies analysts noted that Wave’s performance had an “encouraging efficacy signal,” but that it was “underwhelming; lower vs. competitor.” 

The disappointing outcome follows Wave's decision to ax its experimental Duchenne muscular dystrophy program just last month.